Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 6.786
Filtrar
1.
Syst Rev ; 9(1): 161, 2020 07 18.
Artigo em Inglês | MEDLINE | ID: mdl-32682444

RESUMO

BACKGROUND: Over 4.2 million confirmed cases and more than 285,000 deaths, COVID-19 pandemic continues to harm significant number of people worldwide. Several studies have reported the impact of COVID-19 in general population; however, there is scarcity of information related to pharmacological management and maternal and perinatal outcomes during the pandemic. Altered physiological, anatomical, and immunological response during pregnancy makes it more susceptible to infections. Furthermore, during pregnancy, a woman undergoes multiple interactions with the health care system that increases her chance of getting infected; therefore, managing pregnant population presents a unique challenge. RESEARCH QUESTIONS: This systematic review seeks to answer the following questions in relation to COVID-19: What are the different clinical characteristics presented in maternal and perinatal population? What are the different maternal and perinatal outcome measures reported? What are the distinct therapeutic interventions reported to treat COVID-19? Is it safe to use "medications" used in the treatment of COVID-19 during antenatal, perinatal, postnatal, and breastfeeding? METHOD: The search will follow a comprehensive, sequential three step search strategy. Several databases relevant to COVID-19 and its impact on pregnancy including Medline, CINAHL, and LitCovid will be searched from the inception of the disease until the completion of data collection. The quality of this search strategy will be assessed using Peer Review of Electronic Search Strategies Evidence-Based Checklist (PRESS EBC). An eligibility form will be developed for a transparent screening and inclusion/exclusion of studies. All studies will be sent to RefWorks, and abstraction will be independently performed by two researchers. Risk of bias will be assessed using Cochrane Risk of Bias tool for randomized controlled trials, Newcastle-Ottawa Quality Assessment Scale for non-randomized studies, and for case reports, Murad et al. tool will be used. Decision to conduct meta-analysis will be based on several factors including homogeneity and outcome measures reported; otherwise, a narrative synthesis will be deemed appropriate. DISCUSSION: This systematic review will summarize the existing data on effect of COVID-19 on maternal and perinatal population. Furthermore, to the best of our knowledge, this is the first systematic review addressing therapeutic management and safety of medicines to treat COVID-19 during pregnancy and breastfeeding. SYSTEMATIC REVIEW REGISTRATION: This systematic review has been registered and published with Prospero ( CRD42020172773 ).


Assuntos
Infecções por Coronavirus/tratamento farmacológico , Mortalidade Materna , Mortalidade Perinatal , Pneumonia Viral/tratamento farmacológico , Complicações Infecciosas na Gravidez/tratamento farmacológico , Índice de Apgar , Betacoronavirus , Aleitamento Materno , Feminino , Humanos , Recém-Nascido , Pandemias , Hemorragia Pós-Parto/epidemiologia , Pré-Eclâmpsia/epidemiologia , Gravidez , Sepse/epidemiologia , Resultado do Tratamento
2.
Medicine (Baltimore) ; 99(28): e21198, 2020 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-32664166

RESUMO

INTRODUCTION: Kasabach-Merritt Syndrome (KMS) is an extremely rare disease in adults, which lead to consumptive coagulopathy characterized by severe hypofibrinogenemia and thrombocytopenia. PATIENT CONCERNS:: a 25-year-old Chinese pregnant women complicated by preeclampsia and KMS presented with refractory postpartum hemorrhage and incision bleeding after cesarean section. DIAGNOSIS: The diagnosis of KMS was made based on clinical manifestation of Kaposiform Hemangioendothelioma, severe hypofibrinogenemia and thrombocytopenia. INTERVENTIONS: After a poor response to massive blood products transfusion for 1 week, corticosteroid treatment was initiated for 3 days. OUTCOMES: The patient reached a normal platelet count and a mild anemia within 4 weeks. Two months later, all laboratory values had returned to normal, and the incision was healing well. CONCLUSION: Pregnancy complicated by preeclampsia and surgery may have contributions for the development of Kasabach-Merritt syndrome. Corticosteroid is indicated in the episode of acute Kasabach-Merritt syndrome after the failure of massive blood transfusion.


Assuntos
Corticosteroides/uso terapêutico , Síndrome de Kasabach-Merritt/terapia , Hemorragia Pós-Parto/tratamento farmacológico , Pré-Eclâmpsia/terapia , Complicações Hematológicas na Gravidez/terapia , Adulto , Cesárea , Feminino , Humanos , Síndrome de Kasabach-Merritt/complicações , Hemorragia Pós-Parto/etiologia , Pré-Eclâmpsia/etiologia , Gravidez , Complicações Hematológicas na Gravidez/etiologia
3.
Curr Opin Anaesthesiol ; 33(4): 566-570, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32628404

RESUMO

PURPOSE OF REVIEW: To discuss the recent results of the use of interventional radiology modalities treating postpartum hemorrhage (PPH). RECENT FINDINGS: PPH still is a leading cause of maternal morbidity and mortality. An important risk factor for the development of PPH is the placenta accreta spectrum. In patients with placenta accreta, we can use prophylactic balloon occlusion of the common or internal iliac artery or abdominal aorta to prevent PPH. Balloon occlusion of the abdominal aorta seems to ensure better results than balloon occlusion of the iliac artery in terms of blood loss, transfusion rate and hysterectomy rate reduction with a minimal risk of complications. To treat PPH uterine artery embolization can be effective and potentially fertility-sparing, while having a low complication rate. SUMMARY: The use of aortic balloon occlusion catheters for the prevention of PPH and uterine artery embolization for the treatment of PPH are well tolerated and feasible options for patients with placenta accreta spectrum.


Assuntos
Oclusão com Balão , Placenta Acreta/terapia , Hemorragia Pós-Parto/terapia , Radiologia Intervencionista , Aorta Abdominal , Feminino , Humanos , Obstetrícia , Hemorragia Pós-Parto/prevenção & controle , Gravidez
4.
Zhonghua Yi Xue Za Zhi ; 100(25): 1979-1982, 2020 Jul 07.
Artigo em Chinês | MEDLINE | ID: mdl-32629600

RESUMO

Objective: To investigate the effect of induction on maternal and neonatal outcomes of vaginal birth after cesarean section (VBAC). Methods: Retrospective cohort study. A total of 452 pregnant women who underwent trail of labor after cesarean section (TOLAC) from January 2015 to March 2019 of Beijing Obstetrics and Gynecology Hospital, Capital Medical University were enrolled. According to the mode of the onset of labor, those 331 women who underwent VBAC were divided into spontaneous labor group (n=280) and induction group(n=51). According to induction methods, the pregnant women in the induction group was divided into the low-dose oxytocin subgroup (n=35) and other method subgroup (n=16, 9 cases with cervical ripening by balloon and 7 cases combined with oxytocin). The effect of induction on labor duration and maternal and neonatal outcome in VBAC were analyzed. Results: No maternal and neonatal death occurred. There were 23.0% (76/331) with forceps, 15.1% (50/331) of postpartum hemorrhage, and 24.5% (81/331) of fetal distress. The gravidity, birth weight and the gestational weeks of delivery in the induction group were significantly higher than those in the spontaneous onset group [2.0 (2.0-3.0) vs 2.0(1.0-2.0) times, 39.0(38.0-40.0) vs 38.0(37.0-39.0) weeks, (3 467±372) vs (3 168±538) g, Z=-3.548,-3.892,-3.813, all P<0.01]. The duration of the second stage of labor was significantly longer than that of the spontaneous onset group [43(26-60) vs 30(17-49) min, Z=-2.145,P<0.05], but the duration of the first stage, the total duration of labor, the rate of forceps, the incidence of postpartum hemorrhage, the rate of perineal incision and the incidence of fetal distress were not obvious different (all P>0.05). The duration of the first stage and total duration in oxytocin group were significantly shorter than those other method group [260(210-435) vs 325(250-490) min, 450(355-620) vs 523(370-668) min, Z=-2.001,-1.913, all P<0.05]. There were not significantly different in the duration of second stage, mode of delivery, perineal injury, the rate of postpartum hemorrhage, and fetal distress in the two groups (all P>0.05). Conclusion: Pregnant women who have undergone TOLAC after caesarean section can be induced after fully evaluation. Although induction prolongs the labor duration, it does not affect the maternal and neonatal complication rate.


Assuntos
Hemorragia Pós-Parto , Nascimento Vaginal Após Cesárea , Maturidade Cervical , Feminino , Humanos , Recém-Nascido , Trabalho de Parto Induzido , Gravidez , Estudos Retrospectivos
7.
Anaesth Crit Care Pain Med ; 39(3): 351-353, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32437961
8.
Int J Gynaecol Obstet ; 150(1): 53-57, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32350871

RESUMO

OBJECTIVE: To study vaginal delivery outcomes and neonatal prognosis and summarize the management of vaginal delivery during the COVID-19 pandemic. METHODS: A retrospective analysis of medical records and comparison of vaginal delivery outcomes between 10 pregnant women with clinical diagnosis of COVID-19 and 53 pregnant women without COVID-19 admitted to Zhongnan Hospital of Wuhan University between January 20 and March 2, 2020. Results of laboratory tests, imaging tests, and SARS-CoV-2 nucleic acid tests were also analyzed in neonates delivered by pregnant women with clinical diagnosis of COVID-19. RESULTS: There were no significant differences in gestational age, postpartum hemorrhage, and perineal resection rates between the two groups. There were no significant differences in birth weight of neonates and neonatal asphyxia rates between the two groups. Neonates delivered by pregnant women with clinical diagnosis of COVID-19 tested negative for SARS-CoV-2 infection. CONCLUSIONS: Under the premise of full evaluation of vaginal delivery conditions and strict protection measures, pregnant women with ordinary type COVID-19 can try vaginal delivery without exacerbation of COVID-19 and without increasing the risk of SARS-CoV-2 infection in neonates.


Assuntos
Betacoronavirus , Infecções por Coronavirus/complicações , Parto Obstétrico/métodos , Pneumonia Viral/complicações , Complicações Infecciosas na Gravidez/virologia , Resultado da Gravidez/epidemiologia , Adulto , Peso ao Nascer , China/epidemiologia , Infecções por Coronavirus/transmissão , Infecções por Coronavirus/virologia , Feminino , Hospitalização , Humanos , Recém-Nascido , Transmissão Vertical de Doença Infecciosa/estatística & dados numéricos , Pandemias , Pneumonia Viral/transmissão , Pneumonia Viral/virologia , Hemorragia Pós-Parto/epidemiologia , Hemorragia Pós-Parto/virologia , Gravidez , Estudos Retrospectivos , Vagina/virologia
12.
Clín. investig. ginecol. obstet. (Ed. impr.) ; 47(1): 14-17, ene.-mar. 2020. ilus
Artigo em Espanhol | IBECS | ID: ibc-187067

RESUMO

El tumor trofoblástico del lecho placentario es una de las formas más raras de neoplasia trofoblástica gestacional. Su manifestación clínica más típica es el sangrado vaginal anormal. Debido a su rareza no existe un tratamiento óptimo estandarizado. Presentamos un caso de tumor trofoblástico del lecho placentario con un diagnóstico atípico asociado a una hemorragia posparto que requirió histerectomía obstétrica de urgencia


Placental site trophoblastic tumour is a rare form of gestational trophoblastic disease. The most common clinical manifestation is abnormal vaginal bleeding. Due to its rarity there is no optimal standardised treatment. A case is presented of placental site trophoblastic tumour after an atypical diagnosis associated with a postpartum haemorrhage that required an emergency peri-partum hysterectomy


Assuntos
Humanos , Feminino , Gravidez , Adulto , Neoplasias Trofoblásticas/diagnóstico , Hemorragia Pós-Parto/diagnóstico , Histerectomia/métodos , Neoplasias Trofoblásticas/patologia , Hemorragia Pós-Parto/cirurgia , Neoplasias Trofoblásticas/ultraestrutura , Gonadotropina Coriônica Humana Subunidade beta/sangue , Fatores de Risco
13.
Medicine (Baltimore) ; 99(3): e18792, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-32011478

RESUMO

BACKGROUND: Tranexamic acid (TA) has been demonstrated to reduce blood loss and the incidences of postpartum hemorrhage (PPH) during caesarean sections. We compared the clinical efficacy of TA administration on vaginal deliveries with recently published papers. METHODS: Electronic databases of PubMed, Cochrane Library, Embase and Chinese CNKI (Chinese database) and Wanfang were searched through November 2019.The randomized controlled trials were selected between TA and control groups. The relevant studies included four trials with a total of 4579 patients. RESULTS: Patients treated with TA had a reduction in total blood loss (P = .009), lower postoperative blood loss (P < .00001), a reduced number of PPH (P = .02). However, the occurrence of nausea or/and vomiting is higher in the TA group (the incidence of nausea or vomiting [P < .00001], nausea [P < .00001] and vomiting [P < .00001]). CONCLUSION: TA resulted in fewer occurrence rates of PPH, and no significant increase in occurrences of dizziness or photopsia, but higher incidence of vomiting and nausea.


Assuntos
Antifibrinolíticos/uso terapêutico , Hemorragia Pós-Parto/prevenção & controle , Ácido Tranexâmico/uso terapêutico , Antifibrinolíticos/efeitos adversos , Parto Obstétrico , Feminino , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Ácido Tranexâmico/efeitos adversos
14.
Medicine (Baltimore) ; 99(5): e18943, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-32000415

RESUMO

RATIONALE: The incidence of obstetric hemorrhage due to pernicious placenta previa (PPP) and placenta accreta is currently increasing in China. Parallel transverse uterine incision (PTUI) cesarean section (CS) is a novel technique designed to avoid transecting the placenta and control postpartum hemorrhage during CS in these patients in our hospital. A key point of anesthesia management related to PTUI CS involves keeping the uterus relaxed. General anesthesia (GA) has often been performed, and inhaled volatile anesthetics have traditionally been recommended for this purpose; however, GA may be contraindicated in patients with difficult airways. PATIENT CONCERNS: The patient was predicted to have a difficult airway, and GA may have resulted in potentially life-threatening complications. An alternative and safer method of achieving uterine relaxation during PTUI CS was thus required. DIAGNOSES: The patient was diagnosed with PPP, and a predicted difficult airway was suspected preoperatively. INTERVENTIONS: PTUI CS was planned to control postpartum hemorrhage and preserve fertility during CS. Uterine relaxation during PTUI CS was achieved with intravenous nitroglycerin under combined spinal-epidural anesthesia. OUTCOME: Intravenous nitroglycerin and combined spinal-epidural anesthesia achieved uterine relaxation during the time from delivery of the neonate to making the second transverse incision in the lower segment of the uterus during PTUI CS. Both the parturient and neonate were well and were discharged 4 days later. LESSIONS: Intravenous nitroglycerin and combined spinal-epidural anesthesia may offer an alternative to GA for achieving uterine relaxation in patients with PPP and a predicted difficult airway undergoing PTUI CS to control postpartum hemorrhage.


Assuntos
Cesárea/métodos , Nitroglicerina/uso terapêutico , Placenta Acreta/terapia , Placenta Prévia/terapia , Hemorragia Pós-Parto/prevenção & controle , Vasodilatadores/uso terapêutico , Administração Intravenosa , Adulto , Feminino , Humanos , Gravidez
15.
Medicine (Baltimore) ; 99(7): e19221, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32049861

RESUMO

BACKGROUND: To evaluate the effectiveness and safety of a newly designed intrauterine double-balloon catheter to arrest postpartum hemorrhage (PPH) following cesarean delivery (CD) for placenta previa. METHODS: We conducted an open-label, multicenter randomized controlled trial in two referral centers and one general hospital. Women with continuous bleeding after placental delivery following CD for placenta previa, who failed to respond to uterotonics, suturing and uterine devascularization, and in the absence of suspected deeply invasive accreta were eligible subjects. Eligible subjects were randomized to receive intrauterine double-balloon catheter (n = 102) or gauze packing (n = 102). The main outcome was the rate of successful hemostasis without the need for additional surgical interventions. The secondary outcomes included the volume of blood loss during and after CD, the rate of PPH, incidence and amount of blood transfusion, hysterectomy, surgical complications, intensive care unit admission, need for re-laparotomy, length of hospital stay, and readmission. RESULTS: The 224 participants were recruited before delivery, with 20 excluded (14 cases bleeding stopped after uterotonics and/or local myometrium sutures and 6 patients with placental increta). Finally, 102 women were assigned in catheter group and 102 others in gauze group. There was no difference in the rate of successful hemostasis in the catheter and gauze groups (93.1% vs 91.2%, P = .80). Compared with those in the gauze group, women in the catheter group showed significantly less blood loss within 24 hours postpartum (895 [612.3-1297.8] vs 1156 [882.5-1453.3] ml, P < .01), lower rate of PPH ≥1000 ml (42.2% vs 63.7%, P < .01). Accordingly, women in the catheter group had significantly less maternal adverse events such as postpartum anemia, puerperal morbidity, and postpartum pain. CONCLUSION: Uterine tamponade using a double-balloon catheter was as effective as gauze packing in hemostasis, and appeared to be superior in reducing postpartum blood loss and pain following CD for placenta previa. Using double-balloon catheter in managing PPH in this situation may be a preferable alternative to minimize maternal morbidity.


Assuntos
Cesárea/efeitos adversos , Placenta Prévia , Hemorragia Pós-Parto/prevenção & controle , Tamponamento com Balão Uterino/instrumentação , Adulto , Feminino , Humanos , Hemorragia Pós-Parto/etiologia , Gravidez
16.
West Afr J Med ; 37(1): 74-78, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32030716

RESUMO

PURPOSE: Identification of health problems of women of reproductive age, using a reliable mortality data, is essential in evading preventable female deaths. This study aimed at investigating mortality profile of women of reproductive age group in Nigeria. MATERIALS AND METHODS: This is a descriptive, retrospective study involving women of reproductive age group of 15-49 years that died at DELSUTH from 1st January 2016 to 31st December 2018. The age, date of death and cause of death were retrieved from the hospital records and subsequently analyzed using SPSS version 21. RESULTS: One hundred and eighty-seven eligible deaths were encountered in this study, constituting 17.5% of all deaths in the hospital. Twenty four (12.8%) cases were of maternal etiology while 163 (87.2%) were of non-maternal causes. Non-communicable disease, communicable disease and external injuries accounted for 100 (53.5%), 44 (23.5%) and 19 (10.2%) deaths among the non-maternal causes. The mean age and the peak age group are 34.4 years and the 4th decade respectively. The leading specified non-maternal causes of death (in descending order) are AIDS/TB, cerebrovascular accidents (CVA), breast cancer, road traffic accident (RTA), diabetes, perioperative death and sepsis while the leading maternal causes of death are abortion, postpartum hemorrhage, eclampsia and puerperal sepsis. CONCLUSION: Most deaths affecting WRAG are preventable, with non-maternal causes in excess of maternal causes. There is need for holistic life-long interventional policies and strategies that will address the health need of these women, using evidence-based research findings.


Assuntos
Mortalidade Hospitalar , Hospitais/estatística & dados numéricos , Mortalidade Materna , Aborto Induzido/mortalidade , Adolescente , Adulto , Neoplasias da Mama/mortalidade , Causas de Morte/tendências , Eclampsia/mortalidade , Feminino , Infecções por HIV/mortalidade , Humanos , Mortalidade Materna/tendências , Pessoa de Meia-Idade , Nigéria/epidemiologia , Complicações do Trabalho de Parto/mortalidade , Hemorragia Pós-Parto/mortalidade , Gravidez , Complicações na Gravidez/mortalidade , Infecção Puerperal/mortalidade , Estudos Retrospectivos , Sepse/mortalidade , Acidente Vascular Cerebral , Tuberculose/mortalidade , Adulto Jovem
17.
PLoS One ; 15(2): e0228330, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32027674

RESUMO

Inter-pregnancy interval is an important determinant of both maternal and child health. Suboptimal inter-pregnancy interval has been associated with adverse maternal outcomes -including postpartum hemorrhage and hypertensive disorders, direct causes of maternal mortality. Both overall maternal mortality and the contribution of postpartum hemorrhage on maternal mortality have increased in Tanzania. If we are to achieve sustainable development goal (SDG) number 3.1 to reduce the global maternal mortality ration to less than 70 per 100,000 live births by 2030, it is highly important that such contributors are dealt with. This study aimed to determine the distribution and trends of inter-pregnancy interval and to deduce its association with adverse maternal outcomes among women who delivered at Kilimanjaro Christian Medical Centre (2000-2015).A retrospective cohort study was designed using Kilimanjaro Christian Medical Centre medical birth registry data for women who delivered from 2000 to 2015. Women with at least two births recorded in the registry were included. A total of 7,995 births from 6,612 mothers were analyzed. Anemia during pregnancy, post-partum hemorrhage and pre-eclampsia were adverse maternal outcomes of interest. Data analysis was performed using multivariable logistic regression models allowing for robust standard errors. Crude and adjusted odds ratio with their respective 95% confidence intervals were estimated. More than half (51.7%) of non-first births were born within sub-optimal IPI. The median IPI was 34 months (IQR: 33.5 months). The median IPI increased from 11 months in 2002 to 35 months in 2006 and plateaued until 2014, but it rose to 41.6 months in 2015. Median IPI was shorter in young women <20 years and in birth order seven and above (16 vs. 27 months, respectively). Short IPI was associated with lower risk of pre-eclampsia [aOR: 0.71, 95%CI: 0.52, 0.97] while long IPI was associated with lower risk of post-partum hemorrhage [aOR: 0.70, 95%CI: 0.52, 0.94]. This study found an association between long and short IPI with adverse maternal outcomes. Even though these results should be interpreted with caution based on the fact that the data was sampled from a referral hospital and hence there could be overrepresentation of women with maternal complications, our findings still warrant the importance of supporting modern family planning methods as a measure to improve IPI and thereby improve maternal outcomes as well.


Assuntos
Anemia/diagnóstico , Intervalo entre Nascimentos/estatística & dados numéricos , Hemorragia Pós-Parto/diagnóstico , Pré-Eclâmpsia/diagnóstico , Adulto , Fatores Etários , Feminino , Humanos , Modelos Logísticos , Mortalidade Materna , Razão de Chances , Gravidez , Sistema de Registros , Estudos Retrospectivos , Tanzânia , Adulto Jovem
18.
BMJ ; 368: m237, 2020 02 19.
Artigo em Inglês | MEDLINE | ID: mdl-32075794

RESUMO

OBJECTIVE: To evaluate the risk of adverse maternal and infant outcomes following in utero exposure to duloxetine. DESIGN: Cohort study nested in the Medicaid Analytic eXtract for 2004-13. SETTING: Publicly insured pregnancies in the United States. PARTICIPANTS: Pregnant women 18 to 55 years of age and their liveborn infants. INTERVENTIONS: Duloxetine exposure during the etiologically relevant time window, compared with no exposure to duloxetine, exposure to selective serotonin reuptake inhibitors, exposure to venlafaxine, and exposure to duloxetine before but not during pregnancy. MAIN OUTCOME MEASURES: Congenital malformations overall, cardiac malformations, preterm birth, small for gestational age infant, pre-eclampsia, and postpartum hemorrhage. RESULTS: Cohort sizes ranged from 1.3 to 4.1 million, depending on the outcome. The number of women exposed to duloxetine varied by cohort and exposure contrast and was around 2500-3000 for early pregnancy exposure and 900-950 for late pregnancy exposure. The base risk per 1000 unexposed women was 36.6 (95% confidence interval 36.3 to 36.9) for congenital malformations overall, 13.7 (13.5 to 13.9) for cardiovascular malformations, 107.8 (107.3 to 108.3) for preterm birth, 20.4 (20.1 to 20.6) for small for gestational age infant, 33.6 (33.3 to 33.9) for pre-eclampsia, and 23.3 (23.1 to 23.4) for postpartum hemorrhage. After adjustment for measured potential confounding variables, all baseline characteristics were well balanced for all exposure contrasts. In propensity score adjusted analyses versus unexposed pregnancies, the relative risk was 1.11 (95% confidence interval 0.93 to 1.33) for congenital malformations overall and 1.29 (0.99 to 1.68) for cardiovascular malformations. For preterm birth, the relative risk was 1.01 (0.92 to 1.10) for early exposure and 1.19 (1.04 to 1.37) for late exposure. For small for gestational age infants the relative risks were 1.14 (0.92 to 1.41) and 1.20 (0.83 to 1.72) for early and late pregnancy exposure, respectively, and for pre-eclampsia they were 1.12 (0.96 to 1.31) and 1.04 (0.80 to 1.35). The relative risk for postpartum hemorrhage was 1.53 (1.08 to 2.18). Results from sensitivity analyses were generally consistent with the findings from the main analyses. CONCLUSIONS: On the basis of the evidence available to date, duloxetine is unlikely to be a major teratogen but may be associated with an increased risk of postpartum hemorrhage and a small increased risk of cardiac malformations. While continuing to monitor the safety of duloxetine as data accumulate over time, these potential small increases in risk of relatively uncommon outcomes must be weighed against the benefits of treating depression and pain during pregnancy in a given patient. TRIAL REGISTRATION: EUPAS 15946.


Assuntos
Cloridrato de Duloxetina/efeitos adversos , Complicações na Gravidez/tratamento farmacológico , Resultado da Gravidez/epidemiologia , Inibidores da Recaptação de Serotonina e Norepinefrina/efeitos adversos , Anormalidades Induzidas por Medicamentos/epidemiologia , Anormalidades Induzidas por Medicamentos/etiologia , Adolescente , Adulto , Estudos de Coortes , Cloridrato de Duloxetina/uso terapêutico , Feminino , Cardiopatias Congênitas/induzido quimicamente , Cardiopatias Congênitas/epidemiologia , Humanos , Recém-Nascido Pequeno para a Idade Gestacional , Pessoa de Meia-Idade , Hemorragia Pós-Parto/induzido quimicamente , Hemorragia Pós-Parto/epidemiologia , Pré-Eclâmpsia/induzido quimicamente , Gravidez , Complicações na Gravidez/epidemiologia , Nascimento Prematuro/induzido quimicamente , Nascimento Prematuro/epidemiologia , Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente , Efeitos Tardios da Exposição Pré-Natal/epidemiologia , Inibidores da Recaptação de Serotonina e Norepinefrina/uso terapêutico , Estados Unidos/epidemiologia , Adulto Jovem
19.
Am J Obstet Gynecol ; 222(4): 293.e1-293.e52, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-31917139

RESUMO

OBJECTIVE: To assess the efficacy, effectiveness, and safety of uterine balloon tamponade for treating postpartum hemorrhage. STUDY DESIGN: We searched electronic databases (from their inception to August 2019) and bibliographies. We included randomized controlled trials, nonrandomized studies, and case series that reported on the efficacy, effectiveness, and/or safety of uterine balloon tamponade in women with postpartum hemorrhage. The primary outcome was the success rate of uterine balloon tamponade for treating postpartum hemorrhage (number of uterine balloon tamponade success cases/total number of women treated with uterine balloon tamponade). For meta-analyses, we calculated pooled success rate for all studies, and relative risk with 95% confidence intervals for studies that included a comparative arm. RESULTS: Ninety-one studies, including 4729 women, met inclusion criteria (6 randomized trials, 1 cluster randomized trial, 15 nonrandomized studies, and 69 case series). The overall pooled uterine balloon tamponade success rate was 85.9% (95% confidence interval, 83.9-87.9%). The highest success rates corresponded to uterine atony (87.1%) and placenta previa (86.8%), and the lowest to placenta accreta spectrum (66.7%) and retained products of conception (76.8%). The uterine balloon tamponade success rate was lower in cesarean deliveries (81.7%) than in vaginal deliveries (87.0%). A meta-analysis of 2 randomized trials that compared uterine balloon tamponade vs no uterine balloon tamponade in postpartum hemorrhage due to uterine atony after vaginal delivery showed no significant differences between the study groups in the risk of surgical interventions or maternal death (relative risk, 0.59; 95% confidence interval, 0.02-16.69). A meta-analysis of 2 nonrandomized before-and-after studies showed that introduction of uterine balloon tamponade in protocols for managing severe postpartum hemorrhage significantly decreased the use of arterial embolization (relative risk, 0.29; 95% confidence interval, 0.14-0.63). A nonrandomized cluster study reported that use of invasive procedures was significantly lower in the perinatal network that routinely used uterine balloon tamponade than that which did not use uterine balloon tamponade (3.0/1000 vs 5.1/1000; P < .01). A cluster randomized trial reported that the frequency of postpartum hemorrhage-related invasive procedures and/or maternal death was significantly higher after uterine balloon tamponade introduction than before uterine balloon tamponade introduction (11.6/10,000 vs 6.7/10,000; P = .04). Overall, the frequency of complications attributed to uterine balloon tamponade use was low (≤6.5%). CONCLUSION: Uterine balloon tamponade has a high success rate for treating severe postpartum hemorrhage and appears to be safe. The evidence on uterine balloon tamponade efficacy and effectiveness from randomized and nonrandomized studies is conflicting, with experimental studies suggesting no beneficial effect, in contrast with observational studies. Further research is needed to determine the most effective programmatic and healthcare delivery strategies on uterine balloon tamponade introduction and use.


Assuntos
Hemorragia Pós-Parto/etiologia , Hemorragia Pós-Parto/terapia , Tamponamento com Balão Uterino , Cesárea/estatística & dados numéricos , Feminino , Humanos , Mortalidade Materna , Parto , Placenta Acreta/etiologia , Placenta Prévia/etiologia , Placenta Retida/etiologia , Gravidez , Embolização da Artéria Uterina/estatística & dados numéricos , Tamponamento com Balão Uterino/efeitos adversos , Inércia Uterina/etiologia
20.
Alerta (San Salvador) ; Vol.3(2)ene. 27, 2020. ilus
Artigo em Espanhol | LILACS | ID: biblio-1050925

RESUMO

La hiperpirexia secundaria al uso de misoprostol por la vía sublingual ya ha sido reportada en la literatura; en algunos casos requiere manejo en unidades de cuidados intensivos. Se presenta el caso de una paciente con hemorragia post parto por atonía uterina, quien fue tratada con misoprostol sublingual de 800 microgramos, posteriormente la paciente presentó hiperpirexia, como parte de la evolución clínica y el manejo recibido. La paciente tuvo una buena evolución clínica.


Hyperthermia secondary to the use of sublingual misoprostol is reported in the literature; in some cases, it requires management in intensive care units. We present the case of a patient with postpartum hemorrhage due to uterine atony, who receives an 800 micrograms dose of sublingual misoprostol, subsequently presenting hyperpyrexia, as part of her clinical evolution and management. Currently, the International Federation of Gynecology and Obstetrics recommends an 800 micrograms sublingual dose schedule. A patient with hyperthermia associated with the use of sublingual misoprostol is presented, with good clinical evolution.


Assuntos
Humanos , Gravidez , Hemorragia Pós-Parto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA